普雷西根生物
PGEN
6.39
-0.81
-11.26%
普雷西根生物
US · PGEN
#2527 按市值排名
上市于 1970
6.39
-0.81
-11.26%
实时 - 追踪5344个代码 - 心跳于14秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了1.0个百分点。
机构持股
- 机构持股比例
- 73.40% -0.97pp
- 机构数量
- 247
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund29.06%
Mutual Fund27.99%
Individual/Insider11.71%
Hedge Fund7.43%
Private Company5.54%
Public Company3.06%
Government Pension Fund0.20%
Other14.90%
主要股东 截至 2026-03-30
Third Security, LLC
29.06% · 104.04M 股
Patient Capital Management, LLC
5.32% · 19.04M 股
E. Merck KG
4.88% · 17.47M 股
William Miller
4.86% · 17.39M 股
BlackRock
4.79% · 17.15M 股
Randal Kirk
3.74% · 13.41M 股
State Street Global Advisors
3.35% · 12.00M 股
Diametric Capital, LP
2.59% · 9.27M 股
Vanguard Capital Management, LLC
2.57% · 9.20M 股
Tang Capital Management, LLC
1.79% · 6.42M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 25次买入 · 25次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Third Security, LLC | -- | 29.06% |
| Randal Kirk | Executive Chairperson | 3.74% |
| Helen Sabzevari | Chief Executive Officer | 1.06% |
| Fred Hassan | Independent Director | 0.35% |
| Steve Frank | Independent Director | 0.34% |
| Cesar Alvarez | Independent Director | 0.22% |
| Donald Lehr | Chief Legal Officer | 0.21% |
| Jeffrey Perez | Senior Vice President of Intellectual Property Affairs | 0.21% |
| James Turley | Lead Independent Director | 0.19% |
| Vinita Gupta | Independent Director | 0.19% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-22 | Harry Thomasian | Chief Financial Officer | Derivative Exercise and Retained | +53,665 | $0.96–4.72 |
| 2026-08-25 | Jeffrey Kindler | Independent Director | Open Market Disposition | -185,000 | $7.44 |
| 2026-08-24 | Rutul Shah | Chief Operating Officer | Derivative Exercise and Sale | -50,000 | $2.33–7.50 |
| 2026-08-24 | Rutul Shah | Chief Operating Officer | Intent to Sell (Form 144) | -15,342 | $7.50 |
| 2026-08-24 | Phil Tennant | Chief Commercial Officer | Derivative Exercise and Sale | -79,166 | $1.61–7.50 |
| 2026-08-22 | Harry Thomasian | Chief Financial Officer | Derivative Exercise and Sale | -3,577 | $7.20 |
| 2026-08-22 | Harry Thomasian | Chief Financial Officer | Derivative Exercise and Retained | +3,714 | -- |
| 2026-08-22 | Donald Lehr | Chief Legal Officer | Derivative Exercise and Sale | -2,488 | $7.20 |
| 2026-08-22 | Donald Lehr | Chief Legal Officer | Derivative Exercise and Retained | +2,720 | -- |
| 2026-08-22 | Helen Sabzevari | Chief Executive Officer | Derivative Exercise and Sale | -10,184 | $7.20 |
| 2026-08-22 | Helen Sabzevari | Chief Executive Officer | Derivative Exercise and Retained | +10,649 | -- |
| 2026-08-22 | Rutul Shah | Chief Operating Officer | Sale to Issuer | -3,647 | $7.20 |
| 2026-08-22 | Rutul Shah | Chief Operating Officer | Derivative Exercise and Retained | +7,500 | -- |
| 2026-08-22 | Phil Tennant | Chief Commercial Officer | Sale to Issuer | -2,585 | $7.20 |
| 2026-08-22 | Phil Tennant | Chief Commercial Officer | Derivative Exercise and Retained | +5,208 | -- |
| 2026-08-20 | Nancy Agee | Independent Director | Open Market Acquisition | +3,411 | $7.23 |
| 2026-08-20 | Rutul Shah | Chief Operating Officer | Intent to Sell (Form 144) | -34,658 | $7.50 |
| 2026-08-05 | Rutul Shah | Chief Operating Officer | Automatic Disposition | -32,739 | $6.86 |
| 2026-08-02 | Rutul Shah | Chief Operating Officer | Derivative Exercise and Sale | -33,772 | $2.33–6.50 |
| 2026-07-30 | Harry Thomasian | Chief Financial Officer | Automatic Disposition | -100,000 | $6.06 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:22 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
普雷西根生物 讨论区 0 条评论